Ivermectin and Mebendazole in Cancer Treatment

Nearly half of these cancer patients taking the

ivermectin and mebendazole reported either

cancer disappearance or tumor

regression. And so, and then about thirty percent

reported disease stability, so it wasn't spreading anymore.

So that's a eighty-four point four percent

clinical benefit ratio. In other words, eighty-four point four percent of

those cancer patients did report to have benefited

from the ivermectin and mebendazole. So this is absolutely huge.

We had about two hundred cancer patients.

It is the largest, the single largest human

study on ivermectin and mebendazole in

real human cancer patients. We hope there will be

large randomized double-blind placebo-controlled trials

now from these results as the springboard

because it's very critical. You, you know, everybody knows somebody who's

been affected by cancer, and we gotta stop this, and this

appears to be one way that we may be able to help stop it, at,

at least in a subset of individuals.